Bicycle Therapeutics/$BCYC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicycle Therapeutics
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Ticker
$BCYC
Sector
Primary listing
Employees
305
Headquarters
Website
BCYC Metrics
BasicAdvanced
$490M
-
-$3.50
1.45
-
Price and volume
Market cap
$490M
Beta
1.45
52-week high
$27.11
52-week low
$6.10
Average daily volume
249K
Financial strength
Current ratio
10.388
Quick ratio
10.103
Long term debt to equity
0.264
Total debt to equity
1.076
Interest coverage (TTM)
-1,517.45%
Profitability
EBITDA (TTM)
-281.109
Gross margin (TTM)
-1,083.19%
Net profit margin (TTM)
-1,257.00%
Operating margin (TTM)
-1,495.33%
Effective tax rate (TTM)
2.36%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-19.07%
Return on equity (TTM)
-31.42%
Valuation
Price to revenue (TTM)
25.368
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-2.326
Free cash flow yield (TTM)
-42.99%
Free cash flow per share (TTM)
-3.04
Growth
Revenue change (TTM)
-51.28%
Earnings per share change (TTM)
-6.40%
3-year revenue growth (CAGR)
5.67%
3-year earnings per share growth (CAGR)
4.47%
What the Analysts think about BCYC
Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.
Bulls say / Bears say
Cash and cash equivalents of $721.5 million at quarter-end extend the company’s financial runway into 2028, supporting ongoing clinical programs without immediate financing needs (Reuters ref: turn5view0)
Strategic cost realignment targeting 30% operational savings is set to improve financial efficiency and preserve capital for high-value pipeline advancement (Reuters ref: turn5view0)
Initial human imaging data for the EphA2-targeting program expected in the second half of 2025 provides a key potential catalyst and validation point for the radiopharmaceutical platform (Reuters ref: turn5view0)
Net loss widened to $79 million in Q2 2025, up from $39.8 million a year earlier, highlighting a deepening cash burn amid ongoing clinical development (Reuters ref: turn5view0)
Operating expenses reached $89.52 million in Q2, reflecting substantial R&D spending with uncertain near-term returns as pipeline candidates advance through clinical trials (Reuters ref: turn5view0)
The 30% cost realignment, driven primarily by workforce reductions, signals operational challenges and potential delays as the company restructures to manage expenses (Reuters ref: turn5view0)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BCYC Financial Performance
Revenues and expenses
BCYC Earnings Performance
Company profitability
BCYC News
AllArticlesVideos
Bicycle Therapeutics Strengthens Board of Directors with New Appointments
Business Wire7 days ago
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Business Wire1 month ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicycle Therapeutics stock?
Bicycle Therapeutics (BCYC) has a market cap of $490M as of September 15, 2025.
What is the P/E ratio for Bicycle Therapeutics stock?
The price to earnings (P/E) ratio for Bicycle Therapeutics (BCYC) stock is 0 as of September 15, 2025.
Does Bicycle Therapeutics stock pay dividends?
No, Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Bicycle Therapeutics dividend payment date?
Bicycle Therapeutics (BCYC) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicycle Therapeutics?
Bicycle Therapeutics (BCYC) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.